RETRACTED: HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway (Retracted Article)

被引:21
|
作者
Yang, Guang [1 ]
Zhang, Min [2 ]
Zhao, Yawei [2 ]
Pan, Yue [2 ]
Kan, Mujie [3 ]
Li, Jing [2 ]
He, Kan [2 ]
Zhang, Xuewen [1 ]
机构
[1] Jilin Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Coll Basic Med Sci, Dept Pharmacol, Changchun, Peoples R China
[3] Jilin Univ, Dept Biochem, Coll Basic Med Sci, Changchun, Peoples R China
来源
PLOS ONE | 2020年 / 15卷 / 03期
关键词
EXPRESSION; MICRORNA-122;
D O I
10.1371/journal.pone.0230450
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hepatocellular carcinoma (HCC) is one of the most common human cancers, its prevalence and severity need us to discover novel early diagnostic biomarkers and new therapeutic strategies. MicroRNA-122 is the most abundant microRNA in the liver, and acts as a tumor suppressor and represses HCC development. In our study we showed that HNF-4 alpha and MiR-122 were down-regulated significantly in hepatocellular carcinoma. Over-expression of HNF-4 alpha inhibit hepatocellular carcinoma cells proliferation. And miR-122 is one of the down-stream effector of HNF-4 alpha. Up-regulated miR-122 inhibited hepatocellular carcinoma cells proliferation through regulating ADAM17. Collectively, our results suggested that HNF-4 alpha could inhibit hepatocellular carcinoma proliferation with miR-122 being a downstream target of it. And miR-122 would inhibit hepatocellular carcinoma proliferation by regulating ADAM17 signal pathway.
引用
收藏
页数:10
相关论文
共 50 条
  • [2] RETRACTION: HNF-4a inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway (Retraction of Vol 15, art no E0230450, 2020)
    Yang, G.
    Zhang, M.
    Zhao, Y.
    Pan, Y.
    Kan, M.
    Li, J.
    PLOS ONE, 2023, 18 (03):
  • [3] RETRACTED: Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway (Retracted Article)
    Wang, Linjun
    Xu, Xiangwei
    Chen, Dexing
    Li, Chenghang
    PEERJ, 2023, 11
  • [4] RETRACTED: miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA (Retracted Article)
    Cui, Wenxian
    Li, Yuanguo
    Xu, Keqing
    Chen, Guijin
    Lu, Xiaoqun
    Duan, Qiuqin
    Kang, Zhirong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 479 (04) : 901 - 906
  • [5] RETRACTED: MiR-488 suppresses cell proliferation and invasion by targeting ADAM9 and lncRNA HULC in hepatocellular carcinoma (Retracted Article)
    Hu, Dengdi
    Shen, Dan
    Zhang, Min
    Jiang, Nengmeng
    Sun, Feng
    Yuan, Shibo
    Wan, Kaiming
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (10): : 2070 - 2080
  • [6] RETRACTED: MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4 (Retracted Article)
    Yu, Min
    Lin, Ye
    Zhou, Yu
    Jin, Haosheng
    Hou, Baohua
    Wu, Zhongshi
    Li, Zhide
    Jian, Zhixiang
    Sun, Jian
    ONCOTARGETS AND THERAPY, 2016, 9 : 4705 - 4714
  • [7] RETRACTED: MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma (Retracted Article)
    Zhang, Yongyu
    Yang, Lewei
    Wang, Shiji
    Liu, Zhongmin
    Xiu, Ming
    CANCER BIOMARKERS, 2018, 22 (01) : 151 - 159
  • [8] RETRACTED: Effect of miR-25 on Proliferation of Nasopharyngeal Carcinoma Cells through Wnt/β-Catenin Signaling Pathway (Retracted Article)
    He, Haixia
    Yuan, Kun
    Chen, Wei
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [9] RETRACTED: MiR-16 inhibits pituitary adenoma cell proliferation via the suppression of ERK/MAPK signal pathway (Retracted Article)
    Wang, D. -W.
    Wang, Y. -Q.
    Shu, H. -S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (05) : 1241 - 1248
  • [10] RETRACTED: MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway (Retracted Article)
    Dai, Hong
    Wang, Chunmei
    Yu, Zhihai
    He, Donglin
    Yu, Kun
    Liu, Yin
    Wang, Sheng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2018, 33 (03) : 103 - 109